Alain MOUANGA

Dr. Alain MOUANGA

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
PJPierre Jésus
Pierre Jésus
MGMaëlenn Guerchet
Maëlenn Guerchet
SPSophie Pilleron
Sophie Pilleron
PFPhilippe Fayemendy
Philippe Fayemendy
AMAlain MOUANGA
Alain MOUANGA
JDJean Claude Desport
Jean Claude Desport

11 August 2026 in BMC Public Health
Verified
Journal Article
Open access
PDF file
MBMarcel Tapsou Marcel BAINA
Marcel Tapsou Marcel BAINA
AMAlain MOUANGA
Alain MOUANGA
CVChristevy Vouvoungui
Christevy Vouvoungui
SDSteve Diafouka-Kietela
Steve Diafouka-Kietela
MNMarliti Ngambou Nguissaliki
Marliti Ngambou Nguissaliki
FNFrancine Ntoumi
Francine Ntoumi
Background: Malaria rapid diagnostic tests (mRDTs) are essential for early detection and effective management of malaria, but their success depends on healthcare workers’ (HCWs) knowledge, attitudes, and practices regarding their use. This study described these factors and aimed to identify the key barriers that must be addressed to improve diagnostic malaria practices in the country. Methods: A descriptive cross-sectional study was conducted from November 2024 to February 2025 across 09 health districts in Brazzaville department. Using a two-stage random sampling strategy, 36 public and private primary healthcare facilities were selected, with 211 HCWs involved in malaria diagnosis were enrolled. Data were collected through, a pre-tested semi-structured questionnaire that was self-administered by participants in the presence of the data collector, who provided clarification when participants encountered difficulties understanding certain items, and were analysed using R software (version 4.2.3). Group comparisons of proportions were performed using the Chi-square test (or Fisher’s exact test when expected cell frequencies were below 5. Knowledge, attitude and practice scores were computed from predefined items and classified as good (≥ 75%), intermediate (50–74.9%), or insufficient (< 50%). Results: Among participants, 96% reported using mRDTs, though only 36% had received specific training. General malaria knowledge was low, with just 9% scoring good. Most (90%) had poor understanding of target antigens and diagnostic procedures. However, 97% and 59% perceived mRDTs as easy to use and reliable, respectively. In practice, 85.8% used both mRDTs and microscopy, but only 7.6% followed national guidelines. Following negative mRDTs in symptomatic patients, 39% requested microscopy, and 27% prescribed antimalarials based on clinical suspicion. No significant associations were found between knowledge, attitudes or practices and demographic or professional characteristics. Conclusion: Although mRDTs usage is widespread among HCWs in Brazzaville department, significant gaps persist in their knowledge, attitudes, and practices regarding national diagnostic protocols. Enhanced training and policy enforcement are needed to strengthen malaria case management in the Republic of Congo.

Verified
Journal Article
Open access
PDF file
MDMita Naomie Merveille Naomie merveille DELLO
Mita Naomie Merveille Naomie merveille DELLO
FMFreisnel Hermeland MOUZINGA
Freisnel Hermeland MOUZINGA
Breli Bonheur NgouamaBreli Bonheur Ngouama
Breli Bonheur Ngouama
Darrel Ornelle ELION ASSIANADarrel Ornelle ELION ASSIANA
Darrel Ornelle ELION ASSIANA
DBDechvie Jeannis Melissa BOUMPOUTHOUD
Dechvie Jeannis Melissa BOUMPOUTHOUD
FNFrancine Ntoumi
Francine Ntoumi
Tuberculosis (TB) remains a major global public health concern, further complicated by the emergence and transmission of drug-resistant strains. Diversity within the Mycobacterium tuberculosis complex (MTBC) may also influence disease progression and treatment response. We conducted a longitudinal study among 126 Xpert MTB/RIF Ultra-confirmed TB patients enrolled and followed at the Antituberculosis Center of Brazzaville between July 2023 and November 2024. MTBC species were identified using the Genotype MTBC assay, and resistance-associated mutations in rpoB, katG, and embB were characterized by targeted Oxford Nanopore sequencing and interpreted using the WHO mutation catalogue and TB-Profiler. The overall treatment success rate was 81.7% (103/126). Among 109/126 samples successfully typed, M. tuberculosis accounted for 92.7% (101/109), Mycobacterium africanum for 3.7% (4/109), while mixed infection accounted for 0.9% (1/109) and inconclusive profiles for 2.8% (3/109). Resistance-associated mutations were assessed in 65 of the 126 enrolled patients with high-quality sequencing data. Among these 65 isolates, 32.3% (21/65) harbored resistance to at least one of the targeted first-line drugs, including isoniazid (23.1%; 15/65), rifampicin (15.4%; 10/65), and ethambutol (9.2%; 6/65). Multidrug-resistant TB was identified in 12.3% (8/65). The predominant mutations occurred at rpoB codon 435, katG codon 315, and embB codon 306. Treatment success was lower among patients infected with strains carrying a resistance-associated mutation (71.4%). Isoniazid resistance was associated with reduced odds of treatment success in unadjusted analysis (OR = 0.22, 95% CI: 0.05–0.93; p = 0.04). These findings suggest a considerable burden of genotypically predicted first-line drug resistance and support expanding molecular drug-susceptibility testing beyond rifampicin in TB surveillance and patient management in the Republic of Congo.